ANTHEMAnthem Biosciences Limited Forensic Risk Analysis

Biotechnology
Risk ClassStable
Market Cap₹36,231 Cr
Primary DriverGovernance
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
11 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in governance. This indicates that forensic pressure is currently receding. Risk levels are improving.

100.0th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹755.6▲0.21%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Stability Adjustment
+11.0 pts
Final Composite Risk11 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 11 over 12 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
  • Capex Efficiency Stress
What to Watch Next Quarter
  • Working capital efficiency
  • Inventory turnover
  • Operating profit margins

Active Risk Objects (3)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 272.6%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ2 FY2026
Inventory growth (49.2%) significantly outpaced revenue growth (-73.8%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Capex Efficiency Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight8/15
MomentumAccelerating
Last SignalQ2 FY2026
Aggressive Capex (15.8%) amidst slow revenue growth (-73.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)2.825.11✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+55.0+60.5📈 CRITICAL
Forensic Benchmark Context: Biotechnology (n=2 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹755.6(+0.21%)
1M Divergence-2.86%
1 Week-2.16%
1 Month-0.59%
6 Months+14.14%
1 YearN/A
2 Year-0.47%
3 Year-0.47%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

ANTHEM • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.41%
Trend QualityStabilizing
Phase Progression
Phase Progression Score57.5%
Readiness LabelModerate (Transition Potential Building)
Probability of Advancing41%
CoinTree Momentum
Composite Z-Score+0.1009σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#820 of 2716
Top 30.19% in momentum strength
Timeframe Sparklines
1W-2.2%
1M-0.6%
6M+14.1%
Weinstein Indicators
150 DMA₹685.48
200 DMA₹714.32
150 DMA Slope+0.0518%Rising
Relative Strength+19.63%Leading
Relative Turnover (RTR)0.9774
ParticipationNeutral

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (5.5).
ANTHEMAnthem Biosciences Limited
11 Risk
Sector %ile100th
Delta-5
Active Flags3
Accel+0
Governance

Stable

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Working Capital Expansion

2026

Capex Efficiency Stress

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20262,28059284451